Literature DB >> 21076156

Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.

Sandeep V Pandit1, Sharon Zlochiver, David Filgueiras-Rama, Sergey Mironov, Masatoshi Yamazaki, Steven R Ennis, Sami F Noujaim, Antony J Workman, Omer Berenfeld, Jerome Kalifa, José Jalife.   

Abstract

AIMS: The goal was to terminate atrial fibrillation (AF) by targeting atrioventricular differences in ionic properties. METHODS AND
RESULTS: Optical mapping was used to record electrical activity during carbachol (0.25-0.5 μM)-induced AF in pig hearts. The atrial-specific current, I(Kur), was blocked with 100 μM 4-aminopyridine (4-AP) or with 0.5 μM DPO-1. Hearts in AF and ventricular fibrillation (VF) were also subjected to increasing levels of extracellular K(+) ([K(+)](o): 6-12 mM), compared with controls (4 mM). We hypothesized that due to the more negative steady-state half inactivation voltage for the atrial Na(+) current, I(Na), compared with the ventricle, AF would terminate before VF in hyperkalaemia. Mathematical models were used to interpret experimental findings. The I(Kur) block did not terminate AF in a majority of experiments (6/9 with 4-AP and 3/4 with DPO-1). AF terminated in mild hyperkalaemia ([K(+)](o) ≤ 10.0 mM; N = 8). In contrast, only two of five VF episodes terminated at the maximum ([K(+)](o): 12 mM [K(+)](o)). The I(Kur) block did not terminate a simulated rotor in cholinergic AF because its contribution to repolarization was dwarfed by the large magnitude of the acetylcholine-activated K(+) current (I(K,ACh)). Simulations showed that the lower availability of the atrial Na(+) current at depolarized potentials, and a smaller atrial tissue size compared with the ventricle, could partly explain the earlier termination of AF compared with VF during hyperkalaemia.
CONCLUSION: I(Kur) is an ineffective anti-arrhythmic drug target in cholinergic AF. Manipulating Na(+) current 'availability' might represent a viable anti-arrhythmic strategy in AF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21076156      PMCID: PMC3306132          DOI: 10.1093/cvr/cvq359

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  22 in total

Review 1.  Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Curr Opin Cardiol       Date:  2009-01       Impact factor: 2.161

2.  Mechanisms underlying the antifibrillatory action of hyperkalemia in Guinea pig hearts.

Authors:  Sandeep V Pandit; Mark Warren; Sergey Mironov; Elena G Tolkacheva; Jérôme Kalifa; Omer Berenfeld; José Jalife
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

3.  Properties of a time-dependent potassium current in pig atrium: evidence for a role of kv1.5 in repolarization.

Authors:  Joachim R Ehrlich; Christin Hoche; Pierre Coutu; Christiane Metz-Weidmann; Werner Dittrich; Stefan H Hohnloser; Stanley Nattel; Heinz Gögelein
Journal:  J Pharmacol Exp Ther       Date:  2006-08-17       Impact factor: 4.030

4.  Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation.

Authors:  Sandeep V Pandit; Omer Berenfeld; Justus M B Anumonwo; Roman M Zaritski; James Kneller; Stanley Nattel; José Jalife
Journal:  Biophys J       Date:  2005-03-25       Impact factor: 4.033

Review 5.  Drug therapy for atrial fibrillation: where do we go from here?

Authors:  Richard L Page; Dan M Roden
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

6.  Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.

Authors:  Nathalie Gaborit; Sabrina Le Bouter; Viktoria Szuts; Andras Varro; Denis Escande; Stanley Nattel; Sophie Demolombe
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

Review 7.  Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.

Authors:  Charles Antzelevitch; Alexander Burashnikov
Journal:  J Electrocardiol       Date:  2009-08-20       Impact factor: 1.438

8.  Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

9.  "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.

Authors:  Y Blaauw; H Gögelein; R G Tieleman; A van Hunnik; U Schotten; M A Allessie
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

10.  Can inhibition of IKur promote atrial fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-08-06       Impact factor: 6.343

View more
  23 in total

1.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

2.  Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.

Authors:  Alexander Burashnikov; Alyssa Petroski; Dan Hu; Hector Barajas-Martinez; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-08-30       Impact factor: 6.343

Review 3.  Mathematical approaches to understanding and imaging atrial fibrillation: significance for mechanisms and management.

Authors:  Natalia A Trayanova
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 4.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

5.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

Review 6.  [Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation].

Authors:  David Filgueiras-Rama; Sergio Castrejón; Conrado Calvo; Alejandro Estrada; David Doiny; Marta Ortega; Omer Berenfeld; José L Merino; José Jalife
Journal:  Arch Cardiol Mex       Date:  2012 Apr-Jun

7.  Reduced Na⁺ current density underlies impaired propagation in the diabetic rabbit ventricle.

Authors:  Catherine L Stables; Hassan Musa; Aditi Mitra; Sandesh Bhushal; Makarand Deo; Guadalupe Guerrero-Serna; Sergey Mironov; Manuel Zarzoso; Karen L Vikstrom; William Cawthorn; Sandeep V Pandit
Journal:  J Mol Cell Cardiol       Date:  2014-01-09       Impact factor: 5.000

8.  Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation.

Authors:  Eleonora Grandi; Sandeep V Pandit; Niels Voigt; Antony J Workman; Dobromir Dobrev; José Jalife; Donald M Bers
Journal:  Circ Res       Date:  2011-09-15       Impact factor: 17.367

9.  Minimally invasive system to reliably characterize ventricular electrophysiology from living donors.

Authors:  Aida Oliván-Viguera; María Pérez-Zabalza; Laura García-Mendívil; Konstantinos A Mountris; Sofía Orós-Rodrigo; Estel Ramos-Marquès; José María Vallejo-Gil; Pedro Carlos Fresneda-Roldán; Javier Fañanás-Mastral; Manuel Vázquez-Sancho; Marta Matamala-Adell; Fernando Sorribas-Berjón; Javier André Bellido-Morales; Francisco Javier Mancebón-Sierra; Alexánder Sebastián Vaca-Núñez; Carlos Ballester-Cuenca; Miguel Ángel Marigil; Cristina Pastor; Laura Ordovás; Ralf Köhler; Emiliano Diez; Esther Pueyo
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

Review 10.  Rotors and the dynamics of cardiac fibrillation.

Authors:  Sandeep V Pandit; José Jalife
Journal:  Circ Res       Date:  2013-03-01       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.